Nuclear localized beta-catenin has been found in about 60% clinical pancreatic cancer samples, suggesting the over-activation of beta-catenin/TCF signaling in the progression of pancreatic cancer [7]. This evidence concerns the gene HNF4A and familial pancreatic carcinoma.